Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428433 | 0.90 | IDO1 (0.41) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL2430280 | 0.90 | ADORA3 (0.42) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL1136187 | 0.89 | ALDH1A1 (0.42) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL7261266 | 0.89 | ALDH1A1 (0.46) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL2433158 | 0.87 | ALDH1A1 (0.39) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL7257608 | 0.87 | RET (0.44) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL2433750 | 0.86 | XDH (0.41) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL2430197 | 0.85 | PDE4A (0.40) | IDO1CNR1CNR2 | |
| SCHEMBL2432859 | 0.85 | ADORA3 (0.43) | ALDH1A1CYP3A4NPC1RAB9AKDM4E | |
| SCHEMBL2523334 | 0.84 | PDE4A (0.41) | ALDH1A1CYP3A4NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010064701-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | 大塚製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-6645983-B1 | Heterocyclic imines such as 3-(4-methoxyphenyl)-1,4-dihydro-4 -quinolinone, used as anticarcinogenic agents having cytolysis efficiency; side effect reduction | LABORATOIRE L. LAFON (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1202971-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES | LABORATOIRE L. LAFON (FR) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002022074-A2 | USE OF 2- AND 4- QUINOLONES FOR INHIBITING INTIMAL NEO-PROLIFERATION | LABORATOIRE L. LAFON (FR) | 2002-03-21 | — | — | WO | disclosed |
| WO-2001012607-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES FOR TREATING CANCERS | LABORATOIRE L. LAFON (FR) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | ALDH1A1 568/4885CYP3A4 2014/4885NPC1 1727/4885 |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | ALDH1A1 568/4885CYP3A4 2014/4885NPC1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.